As the world observes World Neglected Tropical Diseases (NTD) Day 2026, global health leaders are celebrating major gains against neglected diseases while raising serious concern over declining financial support. The World Health Organization (WHO) has warned that a 41% decline in NTD aid between 2018 and 2023 threatens to stall or reverse years of progress.

Novo Nordisk has reported encouraging Phase 3 results for CagriSema, its investigational once-weekly treatment for adults with type 2 diabetes, positioning the therapy as a strong next-generation option in an increasingly competitive metabolic disease market. The findings come from the REIMAGINE-2 trial, where the combination therapy delivered superior glycaemic control and weight reduction compared to semaglutide alone.